Role of Platelet-Rich Plasma in Treatment of Primary Atrophic Rhinitis

Introduction: Atrophic rhinitis (AR) is a chronic condition characterized by progressive atrophy of the nasal mucosa and underlying bone. AR can be classified as either primary or secondary to a predisposing factor or an event. Platelet-Rich Plasma (PRP) is a platelet-rich concentrate of plasma proteins and growth factors that aids in regeneration of nasal mucosa. Aim and Objectives of the study: Evaluation of efficacy of PRP injection in Primary Atrophic Rhinitis (PAR). Objectives: (1). To analyse Sino-Nasal Outcome Test-25(SNOT-25) scores before & after PRP therapy in patients with PAR. (2). To study any local side effects following PRP injection. Methodology: The Hospital based prospective cohort study was conducted in Department of Otorhinolaryngology, Deen Dayal Upadhyay Hospital, and New Delhi from May 2022 to May 2023. Autologous PRP was given intranasally at 0, 2 and 4 weeks interval. Outcome measures - Primary- Improvement in SNOT-25 scores. Secondary- Improvement in nasal symptoms like nasal crusting and nasal obstruction. Results: In this study, The SNOT-25 scores showed improvement over 6 months follow-up period, suggesting tissue regeneration and wound healing. The mean ± SD SNOT-25 score at 0, 1 and 6 months was found to be 44.08±4.12, 25.18±8.42 and 10.48±4.61 respectively. Nasal symptoms like nasal crusting and nasal obstruction also improved. Conclusions: In the present study autologous PRP was given in patients of PAR intranasally with good results without any complications. SNOT-25 score and nasal symptoms showed significant improvement after PRP injection in 6 months follow-up period.